Archive | Health Professionals

Treatment With Dabrafenib, Trametinib Demonstrates High Relapse-free Survival Rate in Melanoma Patients

More than half of high-risk patients with resected, stage III BRAF V600-mutated melanoma who were treated with dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) were alive and relapse-free at 5 years, according to a recent study published in The New England Journal of Medicine.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest

Dr. Garutti on the Potential Shift to Neoadjuvant Therapy in Melanoma

Mattia Garutti, MD, medical oncologist, Unit of Clinical Oncology, Centro di Riferimento Oncologico di Aviano, Aviano, Italy, discusses the potential shift to neoadjuvant therapy in melanoma.

Read the full story

Posted in Melanoma News, Health Professionals, Video Reports

Dr. Shoushtari on the Design of the CheckMate-067 Trial in Advanced Melanoma

Alexander N. Shoushtari, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the design of the ?phase 3 CheckMate-067 trial in advanced melanoma.

Read the full story

Posted in Melanoma News, Health Professionals, Video Reports

Asian Americans and Pacific Islanders Have Poorer Melanoma Outcomes than White Patients

Asian Americans and Pacific Islanders (API) are diagnosed less frequently with skin cancer than White Americans. But they have higher mortality rates once diagnosed, a new study shows.

Read the full story

Posted in Melanoma News, Health Professionals, Of Interest